ABSTRACT
Radiotherapy is the most common treatment for nasopharyngeal carcinoma, and the radiotherapy technique is essential for the prognosis of nasopharyngeal carcinoma. Due to the complexity of the structure of the intensity-modulated device and the accuracy of the clinical requirements of radiotherapy, it is inevitable that higher requirements will be imposed on the process of intensity-modulated radiotherapy. Currently, gaps exist in the radiotherapy equipment and personnel qualification among radiotherapy units, and thus the homogenization in the radiotherapy remains to be strengthened in China. With the application of radiotherapy information management system, digital medicine and artificial intelligence technologies in the field of radiotherapy, the original process fails to meet the application needs of the new precise radiotherapy technology. Therefore, this process is designed based on the existing radiotherapy procedures for nasopharyngeal carcinoma in combination with the latest developments in the field of radiotherapy, aiming to establish a novel standard process recommendation, ensuring the standardization and homogenization of radiotherapy and achieve the individualized intensity-modulated radiotherapy for nasopharyngeal carcinoma patients.
ABSTRACT
OBJECTIVE:To observe short-term efficacy and ADR of nedaplatin concurrent chemoradiotherapy combined with thermotherapy in the treatment of middle and advanced esophageal cancer. METHODS:64 patients with middle and advanced esophageal cancer were randomly divided into control group and treatment group,with 32 cases in each group. Control group was given nedaplatin concurrent chemoradiotherapy,nedaplatin 30 mg/m2,ivgtt,every week during chemotherapy;treatment group re-ceived thermotherapy by high frequency heating machine before chemoradiotherapy,60 min/time,twice a week;received chemora-diotherapy 30 min after thermotherapy. Short-term efficacy and ADR were observed in 2 groups. RESULTS:The short-term total effective rate of treatment group(84.4%)was higher than that of control group(62.5%),with statistical significance(P<0.05). The incidence of bone marrow suppression,radioactive esophagitis and gastrointestinal reactions in treatment group vs. control group were(21.9%)vs.(46.9%),(18.8%)vs.(56.3%),(31.3%)vs.(59.4%),with statistical significance(P<0.05). CONCLU-SIONS:Nedaplatin concurrent chemoradiotherapy combined with thermotherapy is better than concurrent chemoradiotherapy in the treatment of middle and advanced esophageal cancer with low incidence of ADR.